Joseph Sparano, MD, Icahn School of Medicine at Mount Sinai, New York, NY, addresses strategies to ensure artificial intelligence (AI) diagnostic tools do not perpetuate health disparities and emphasizes the importance of validating AI performance across diverse patient populations. Dr Sparano highlights that only 3% of US cancer patients enroll in clinical trials, with minority subjects representing just 10-15% of participants. In the TAILORx cohort, approximately 8-9% of patients were Black and 15% were Hispanic, with analysis revealing worse outcomes in Black patients with estrogen receptor-positive/HER2-negative breast cancer, disparities that appear driven by factors beyond access to care. Dr Sparano emphasizes the critical need to increase overall clinical trial enrollment and improve minority access to trials for equitable AI development. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2025 Meeting in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
